A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/22165

Title:	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
Authors:	Salazar, Ramon Capdevila, Jaume Laquente, Berta Manzano, Jose Luis Pericay, Carles Villacampa, Mercedes Martínez López, Carlos Losa, Ferran Safont, Maria Jose Gómez, Auxiliadora Alonso, Vicente Escudero, Pilar Gallego, Javier Sastre, Javier Grávalos, Cristina Biondo, Sebastiano Palacios, Amalia Aranda, Enrique View more
Mesh:	Adult Aged Antineoplastic Combined Chemotherapy Protocols Bevacizumab Biomarkers, Tumor Capecitabine Chemoradiotherapy, Adjuvant Drug Administration Schedule Female Humans Male Middle Aged Patient Compliance Preoperative Period Radiotherapy Dosage Rectal Neoplasms Treatment Outcome View more
Issue Date:	26-Feb-2015
Citation:	BMC Cancer.2015 Feb;(15):60
Abstract:	Perioperatory chemoradiotherapy (CRT) improves local control and survival in patients with locally advanced rectal cancer (LARC). The objective of the current study was to evaluate the addition of bevacizumab (BEV) to preoperative capecitabine (CAP)-based CRT in LARC, and to explore biomarkers for downstaging.
PMID:	25886378
URI:	https://hdl.handle.net/20.500.12530/22165
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:

File	Description	Size	Format
PMC4343271.pdf		530.64 kB	Adobe PDF	View/Open